Sinotau Pharmaceutical
Sinotau Pharmaceutical is a China-based radiopharmaceutical company running 2 late-stage cancer trials of Octreotide LAR in neuroendocrine tumours.
Overview
Sinotau Pharmaceutical, based in Beijing, China, is a radiopharmaceutical company. Sinotau specialises in the research and development, production, clinical application and academic promotion of radiopharmaceutical drugs, with therapeutic focus areas in oncology, neurology and cardiology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Octreotide LAR in neuroendocrine tumours. The largest, NCT05459844 (A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs), plans to enrol 196 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
not linked directly; found by shared links- PersonSimron Singh
Shares Neuroendocrine tumours, Lutetium-177.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Neuroendocrine tumours, Lutetium-177.
- PersonEmily K. Bergsland
Shares Neuroendocrine tumours, Lutetium-177.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Neuroendocrine tumours, Lutetium-177.
- TermRenal protection with amino acid co-infusion
Shares Neuroendocrine tumours, Lutetium-177.
- CompanyMolecular Targeting Technologies
Shares Neuroendocrine tumours, Lutetium-177.
- Key paperResults and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms
Shares Neuroendocrine tumours, Lutetium-177.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Neuroendocrine tumours, Lutetium-177.